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Introduction {#sec1}
============

Alzheimer's disease (AD) is a devastating disorder of the brain and a rapidly growing public health problem. Patients with rare mutations in the amyloid precursor protein (*APP*) and presenilin 1 and 2 genes (*PSEN 1* and *PSEN 2*) make up about 5% of familial AD cases (FAD) while the vast majority of AD is late-onset, sporadic AD (SAD) ([@bib3]). SAD is a complex and heterogeneous disorder with a clear heritable component that defines genetic risk ([@bib14]) but with unknown contributions from the environment. The lack of effective therapies for AD is, in large part, due to our lack of understanding of the cellular and molecular mechanisms that lead to the neuropathological outcomes of the disease. Reasons for this are several-fold. In particular, AD takes decades to manifest clinically, and irreversible cellular damage likely occurs before the overt clinical symptoms are detected. In addition, the human brain is an inaccessible organ, making it difficult to sample tissue from living patients. Human induced pluripotent stem cells (hiPSCs) have facilitated the development of human neuronal models for AD, as they can be differentiated into disease-appropriate cell types and maintain the unique patient genetic background. To date, AD has been successfully modeled using patient and isogenic cell lines, and disease-relevant phenotypes have been well-documented from stem cell-derived neurons for both FAD and SAD ([@bib18], [@bib21], [@bib29], [@bib32], [@bib44], [@bib45], [@bib47]).

We and others have demonstrated a role for endocytic genes in AD risk ([@bib19], [@bib35], [@bib47]), and elegant microscopic analysis has documented enlarged endosomes and suggested endocytic dysfunction as an early phenotype in AD pathogenesis ([@bib10], [@bib9], [@bib30]). This work has been recapitulated in stem cell-derived neurons ([@bib18], [@bib32]); however, to date, no AD therapy targets the endosomal network, likely due to the complexity of its structure and regulation.

Retromer is a multiprotein assembly with a primary role in the sorting and trafficking of plasma membrane proteins from the endosomes, to the *trans*-Golgi network, or directly back to the cell surface ([@bib17]). APP is trafficked through the endocytic network via retromer through its interaction with SORLA, a member of the vacuolar protein-sorting VPS10 family of sorting receptors and a well-defined AD risk gene ([@bib13], [@bib33], [@bib34], [@bib35]). The retromer assembly has two major components, including the cargo-recognition complex (CRC), a trimeric core composed of VPS35, VPS29, and VPS26 ([@bib23]). The second component of retromer comprises the membrane targeting specific nexins, chiefly SNX1, SNX3, SNX5, SNX6, and SNX27 ([@bib8]). Retromer deficiency, primarily loss of VPS35 and VPS26, has been described in SAD patients and increases Aβ peptides in cell culture and cognitive decline in the mouse brain ([@bib6], [@bib28], [@bib40], [@bib42]).

Recently, novel pharmacological chaperones were developed that stabilize the trimeric core complex of VPS35, VPS29, and VPS26. These molecules, R33 and R55, reduced Aβ in mouse hippocampal neurons in a retromer-dependent manner ([@bib25]). Similarly, the retromer stabilization molecule R55 reduced Aβ in in a murine neuronal cell line harboring the APP Swedish mutation ([@bib12]). These studies support the idea that increasing the levels and/or functions of endocytic trafficking components may be viable options for therapeutic development in AD. However, to move forward in investigation of therapeutic strategies for humans, it is critical to test candidates in a human-specific system. In addition, while Aβ is a critical pathogenic readout for AD, how retromer stabilization affects other components of the disease process, such as TAU hyperphosphorylation, and if these two events are interdependent, is unknown. To address these questions, we used hiPSC-derived neurons from SAD and FAD patients and from genome-edited hiPSC lines. This allowed us to modulate the amounts of Aβ generation and APP expression in neurons and test how retromer stabilization by the small molecule chaperone R33 affects endogenous levels of Aβ and phospho-TAU (pTAU) in a human-specific system.

Results {#sec2}
=======

Retromer Pharmacological Chaperones Reduce APP Processing and Aβ Peptides in hiPSC-Derived Neurons from Non-demented Controls, SAD Patients, and FAD Mutant Cells {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

The pharmacological chaperone R55 was previously shown to stabilize the retromer core complex, reduce Aβ peptides, and decrease APP in endosomes in mouse primary hippocampal neurons, suggesting that retromer stabilization is beneficial in terms of AD pathogenesis ([@bib25]). We extended these studies to test the effect of retromer stabilization in human neurons using an hiPSC approach. We tested both R55 and its analog R33 in FACS-purified neurons derived from non-demented control (NDC) hiPSCs. Our differentiation protocol has consistently been shown to recapitulate key cellular AD phenotypes in a purified system, allowing us to accurately quantitate analytes coming from a particular cell type (i.e., human neurons) ([@bib18], [@bib47]). We found that, in contrast to mouse neurons, R33 had a greater effect on Aβ peptide reduction than R55 in human neurons differentiated from hiPSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}).

We then tested a cohort of cell lines derived from participants in the University of California, San Diego (UCSD) Alzheimer\'s Disease Research Center (ADRC), which included six NDCs and seven SAD patients (n = 13 patient cell lines) ([Figure 1](#fig1){ref-type="fig"}A). We found that in cell lines derived from either NDC or SAD subjects, R33 treatment for 72 hr significantly reduced both Aβ 1--40 and 1--42 peptide species ([Figures 1](#fig1){ref-type="fig"}B--1E). Because this reduction occurred equally for both Aβ species, we did not observe significant changes in the Aβ 42:40 ratio ([Figures 1](#fig1){ref-type="fig"}F and 1G). This is similar to what was previously observed in mouse hippocampal neurons, where retromer stabilization decreased Aβ 40 and 42 peptides equally ([@bib25]). We observed variability among neuronal cultures in the amount of increase in VPS35 stability, which could be due to inherent variability between hiPSC lines, individual patient genomes, or the limited amount of material obtained from our purified neuron protocol ([Figure S2](#mmc1){ref-type="supplementary-material"}A). However, in representative experiments, we documented detectable increases in VPS35 stability from purified neuronal cultures ([Figure S2](#mmc1){ref-type="supplementary-material"}B).Figure 1Retromer Stabilizing Chaperone R33 Lowers Aβ Peptides in hiPSC-Derived Neurons(A) Schematic diagram of experimental design. hiPSCs were generated from fibroblast biopsies of six NDCs and seven probable SAD patients from the UCSD ADRC. These lines have been previously published and characterized in [@bib18] and [@bib47]. FACS purified neural stem cells and purified neurons were generated following previously published methods ([@bib18], [@bib48]).(B and C) Aβ~1-40~ (B) and Aβ~1-42~ (C) peptides in purified neurons derived from NDC individuals treated with vehicle (dots) or R33 (squares) for 72 hr.(D and E) Aβ~1-40~ (D) and Aβ~1-42~ (E) peptides in purified neurons derived from SAD patients treated with vehicle (dots) or R33 (squares) for 72 hr.(F and G) Aβ 42:40 ratios in purified neurons derived from NDC (F) or SAD (G) patients treated with vehicle (dots) or R33 (squares) for 72 hr. n = 6 NDC individuals (represented by dots/squares); two to four independent experiments/individual/treatment. n = 7 SAD individuals (represented by dots/squares); two to four independent experiments/treatment.Non-normally distributed data (A--E) were analyzed by Wilcoxon test. ^∗^p \< 0.05. Normally distributed data (F and G) were analyzed by two-tailed t test. NS, nonsignificant. All error bars represent SD. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

We next asked if retromer stabilization by R33 had an effect in genetic backgrounds of penetrant mutations leading to early-onset, FAD, either by increasing the levels of APP (APP duplication, APP^Dp^) or by enhancing beta cleavage of APP (APP Swedish, APP^Swe^). In either patient neurons from FAD APP^Dp^ ([@bib18]) or in isogenic neurons in which the Swedish mutation was introduced via CRISPR/Cas9 genome editing ([Figure S2](#mmc1){ref-type="supplementary-material"}D) ([@bib43]), we observed a similar fold-decrease in Aβ peptides from APP^Dp^ patients and the APP^Swe^ isogenic neurons as with the NDC and SAD patient neurons ([Figures 2](#fig2){ref-type="fig"}A and 2B), suggesting that this small molecule chaperone is a potent reducer of Aβ, despite patient or cell line genetic background. Indeed, we observed a significant decrease in all forms of APP processing ([Figure 2](#fig2){ref-type="fig"}C) and observed a reduction in APP β-CTF in purified neurons treated with R33 ([Figure 2](#fig2){ref-type="fig"}D). Interestingly, we did not observe a significant increase in FL APP ([Figure S2](#mmc1){ref-type="supplementary-material"}C), although this may be due to the variability of APP expression across all our different patient genetic backgrounds and the dynamic process between APP cleavage and recycling, where changes in APP cleavage may affect the overall expression of APP. Future experiments are needed to determine how retromer stabilization affects these processes. Taken together, these data corroborate previous work in the mouse and suggest that retromer stabilization keeps APP out of intracellular compartments that generate β-cleavage of APP and, subsequently, Aβ.Figure 2Retromer Stabilization Reduces Aβ Peptides in FAD Mutant Genetic Backgrounds and Reduces Overall APP Processing in Human Neurons(A) R33 treatment significantly reduces Aβ peptides in hiPSC-derived neurons generated from a patient with an APP duplication mutation (APP^Dp^). n = 1 FAD individual, three independent experiments/treatment.(B) R33 treatment significantly reduces Aβ peptides in CRISPR/Cas9 gene-edited isogenic neurons where the APP Swedish (APP^Swe^) mutation was introduced into wild-type (WT) cells by homologous recombination n = 1--2 isogenic clones/genotype, three independent experiments/treatment.(C and D) R33 treatment reduces all APP processing in human neurons, including Aβ sAPPα, sAPPβ (C), and APP β CTF (D). n = 3 independent experiments/treatment.For each comparison, a two-tailed t test was performed. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Error bars represent SD. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Retromer Pharmacological Chaperones Reduce the Phospho-TAU/Total TAU Ratio in hiPSC-Derived Neurons by Decreasing the Level of Phosphorylated TAU on Thr231 {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

In addition to amyloid plaques, another neuropathological hallmark of AD is the presence of neurofibrillary tangles comprising hyperphosphorylated TAU protein. The connection between Aβ and TAU is complex, with the dominant theory that Aβ pathology precedes and drives TAU pathology ([@bib16]), while other evidence suggests that these pathways can occur independently ([@bib39]). Neurons purified from hiPSCs have detectable levels of phosphorylated TAU on Thr231 and this correlates with increases in Aβ from APP^Dp^ patients ([@bib18]). We tested the effect of retromer stabilization by R33 on the pTAU/total TAU (tTAU) ratio on our cohort of patient neurons and found that R33 treatment significantly decreased the pTAU/tTAU ratio in all cell lines, whether they were derived from NDC or SAD individuals ([Figures 3](#fig3){ref-type="fig"}A and 3B). Interestingly, this decrease in the ratio was due to an effect on pTAU ([Figure 3](#fig3){ref-type="fig"}C), while the levels of tTAU in the cultures remained unchanged ([Figure 3](#fig3){ref-type="fig"}D). R33 treatment had a similar effect on neurons derived from an APP^Dp^ patient, with a reduction of pTAU ([Figure 3](#fig3){ref-type="fig"}E), but not tTAU ([Figure 3](#fig3){ref-type="fig"}F), leading to a lowered pTAU/tTAU ratio in these neurons ([Figure 3](#fig3){ref-type="fig"}G).Figure 3Retromer Stabilization Reduces the pTAU/tTAU Ratio in hiPSC-Derived Neurons(A) pTAU/tTAU ratio in purified neurons derived from NDC individuals treated with vehicle (dots) or R33 (squares) for 72 hr. n = 6 NDC individuals (represented by dots/squares); two to four independent experiments/individual/treatment.(B) pTAU/tTAU ratio in purified neurons derived from NDC (SAD) individuals treated with vehicle (dots) or R33 (squares) for 72 hr. n = 7 SAD individuals (represented by dots/squares); two to four independent experiments/treatment.(C) R33 reduces the TAU ratio by lowering phosphorylated TAU on Thr 231 in all samples (NDC and SAD neurons). n = 13 individuals (SAD + NDC) represented by dots/squares; two to four independent experiments/treatment.(D) Levels of tTAU in all samples (NDC and SAD neurons) are unaffected by R33 treatment. n = 13 individuals (SAD + NDC) represented by dots/squares; two to four independent experiments/treatment.(E) R33 reduces pTAU (Thr 231) in hiPSC neurons derived from an APP duplication patient.(F) R33 does not affect tTAU levels in APP duplication neurons.(G) R33 decreases the pTAU/tTAU ratio in APP duplication neurons.Non-normally distributed data (A--D) were analyzed by Wilcoxon test. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001. NS, nonsignificant. Error bars represent SD. (E--G) For APP duplication: n = 1 FAD individual, three independent experiments/treatment. For each comparison, a two-tailed t test was performed. ^∗∗^p \< 0.01. NS, nonsignificant. Error bars represent SD. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

We probed a second pTAU epitope, paired helical fragment (PHF) TAU, and observed that in the presence of compound E, a gamma-secretase inhibitor, levels of PHF TAU increased, but when neurons were concomitantly treated with both compound E and R33, the PHF signal decreased ([Figure S3](#mmc1){ref-type="supplementary-material"}A). We tested whether R33 affected the activation of the TAU kinase GSK3β ([Figure S3](#mmc1){ref-type="supplementary-material"}B); however, we did not observe a significant effect of R33 treatment on the activity of GSK3β, suggesting that the decrease in pTAU by R33 is mediated through a different mechanism.

Finally, we tested whether other molecules hypothesized to be neurotrophic or protective against AD phenotypes had a similar effect to R33 on the pTAU/tTAU ratio. We have previously shown that the neurotrophin brain-derived neurotrophic factor (BDNF) reduced Aβ peptides in stem cell-derived neurons and that this reduction was correlated with protective variants in the *SORL1* gene, whose protein product, SORLA, is a receptor of the retromer complex ([@bib47]). BDNF has been shown to reduce TAU phosphorylation, although at a different epitope than is analyzed in this study, in retinoic acid-differentiated SH-SY5Y cells ([@bib11]). We treated hiPSC-derived neurons from three cell lines harboring *SORL1* protective variants with BDNF and measured the pTAU/tTAU ratio. Under these conditions, however, we did not observe a significant change in the TAU ratio ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Taken together, these data suggest that the decrease in the pTAU/tTAU ratio by R33 has a more specific effect on the stabilization of the trimeric core cargo-recognition complex than on the various retromer receptor or interacting proteins.

Genetic Knockdown of VPS35 Increases Aβ and Phospho-TAU in Stem Cell-Derived Neurons {#sec2.3}
------------------------------------------------------------------------------------

We next tested whether destabilization of the retromer complex by knockdown of VPS35 had the opposite effect of R33 treatment in hiPSC-derived neurons. Using lentiviral transduction, we expressed two independent short hairpin RNAs (shRNAs) against *VPS35* mRNA (determined from a pool of four shRNAs, [Figure S4](#mmc1){ref-type="supplementary-material"}A) in purified neurons and documented significant increases in Aβ peptides similar to what has been previously reported in mice ([Figures 4](#fig4){ref-type="fig"}A and 4B) ([@bib6]). We next measured phosphorylated TAU protein (Thr 231) from purified neurons transduced with two VPS35 shRNA and observed a small but significant increase in pTAU at Thr 231 ([Figure 4](#fig4){ref-type="fig"}C). The magnitude of the increase in pTAU after VPS35 knockdown is similar to that of the decrease in pTAU we observe after R33 treatment. Because shRNA VPS35-c gave the strongest effect, we confirmed the knockdown of VPS35 protein and *VPS35* mRNA using that shRNA in multiple experiments ([Figures 4](#fig4){ref-type="fig"}D and 4E). We consistently observed an approximately 50% knockdown of VPS35 protein in our neuronal cultures ([Figure 4](#fig4){ref-type="fig"}D). Although we are only able to reduce the levels of VPS35 protein by half, it should be noted that germline deletion of VPS35 is results in embryonic lethality in mice and haploinsufficiency of VPS35 is sufficient to increase AD neuropathology in a transgenic mouse model ([@bib42]). These data suggest that even modest changes in retromer subunit levels may have a large impact on cellular phenotypes. In terms of AD, we note that duplication of APP resulting in one extra copy of the gene and 50% more *APP* expression is sufficient to cause severe and early-onset AD ([@bib37]). Thus, for factors that may increase or decrease risk but not the deterministic probability of AD, changes on the order of 20% are likely relevant in human disease.Figure 4Knockdown of Retromer Assembly Subunit VPS35 by shRNA Increases Aβ and pTAU/tTAU Ratio in hiPSC-Derived Neurons(A and B) Aβ peptides (A, Aβ~1-40~; B, Aβ~1-42~) measured from the cell culture media of hiPSC-derived neurons are increased when VPS35 levels are reduced by VPS35 shRNA (two shRNA, *VPS35*-c and *VPS35*-d) compared with a scrambled shRNA (SCR shRNA).(C) pTAU levels increase in hiPSC-derived neurons when VPS35 levels are reduced by VPS35 shRNA (two shRNA, c and d) compared with scrambled shRNA (SCR shRNA).(D) VPS35 shRNA-c reduces VPS35 protein by 50%.(E) VPS 35 shRNA-c reduces VPS35 mRNA by 50%. n = 4 independent experiments per treatment/condition.(A--C) For each comparison, a one-way ANOVA with a Tukey multiple comparisons posttest was performed. (D and E) For each comparison, a two-tailed t test was performed. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p\<0.001. Error bars represent SD. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Phospho-TAU Reduction Correlates with, but Is Not Dependent on, Aβ Peptide Levels {#sec2.4}
---------------------------------------------------------------------------------

Because the magnitude of decrease in pTAU after R33 treatment was similar to the decreases observed in APP processing, we performed a linear regression analysis on absolute levels of pTAU and absolute levels of Aβ in the cultures across all 13 patient cell lines and found a positive correlation between the reduction of Aβ and the reduction in pTAU ([Figure 5](#fig5){ref-type="fig"}A). Previous work in hiPSC-derived neurons has suggested that beta cleavage of APP, rather than Aβ, is more highly associated with TAU phosphorylation ([@bib18]), so we also examined the levels of sAPPβ compared with pTAU and observed a similar, but less robust, correlation between the reduction in sAPPβ with pTAU ([Figure 5](#fig5){ref-type="fig"}B). Taken together, however, these data suggest that the reduction in pTAU by R33 is highly correlative with a reduction in amyloidogenic processing of APP.Figure 5The Decrease of Phosphorylated TAU Mediated by Retromer Stabilization Is Correlative with, but Not Dependent on, Decreases in Aβ and sAPPβ(A) Absolute levels of Aβ peptides from 13 patient cell lines were graphed against absolute values of pTAU from hiPSC-derived neurons and show a positive correlation between decreases in Aβ and decreases in pTAU.(B) Absolute levels of sAPPβ peptides from 13 patient cell lines were graphed against absolute values of pTAU from hiPSC-derived neurons and show a positive correlation between decreases in sAPPβ and decreases in pTAU.(C) hiPSC neurons with the APP Swedish (Swe) mutation introduced by genome editing show substantial increases in Aβ peptides in either heterozygous (Swe/wild-type \[WT\]) or homozygous (Swe/Swe) genotypes compared with the WT isogenic controls.(D) Increased levels of Aβ peptides do not affect the observed decrease in the pTAU/tTAU ratio mediated by R33 treatment.(E) Compound E treatment substantially decreases Aβ peptides in hiPSC-derived neurons and treatment with R33 further decreases Aβ peptides in this condition, ^∗∗∗^ represents statistical difference from vehicle; ^∗^ represents statistical difference between compound E alone and compound E + R33.(F) Aβ reduction does not change the fold-decrease in the pTAU/tTAU ratio mediated by R33.(A and B) A linear regression analysis was performed between Aβ and pTAU (A) and sAPPβ and pTAU (B). *R*^2^ values reported on graphs. (C) For each comparison, a one-way ANOVA with a Tukey multiple comparisons posttest was performed. (D and F) For each comparison, a two-tailed t test was performed. n = 3 independent experiments per treatment/condition.Error bars represent SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.

We next asked if modulation of Aβ levels affected the decrease in pTAU by R33. We measured pTAU from isogenic neurons harboring the APP Swedish mutation, which leads to a 2- to 3-fold increase in endogenous Aβ in heterozygous and homozygous carriers, respectively ([Figure 5](#fig5){ref-type="fig"}C). Interestingly, we did not observe increased levels of pTAU/tTAU ratio in cells harboring these mutations alone. Previous work using isogenic cell lines of another penetrant AD mutation, *PSEN1*ΔE9, also failed to show increased pTAU/tTAU ratios at baseline conditions ([@bib44]). However, treatment with R33 reduced the pTAU/tTAU ratio in the isogenic neurons to the same extent across this allelic series, with no significant difference in R33-mediated TAU ratio reduction between the wild-type cells and the Swedish genotypes ([Figure 5](#fig5){ref-type="fig"}D), suggesting that retromer stabilization reduces TAU phosphorylation regardless of genetic condition. To test whether modulating level of the APP β-CTF in our cell cultures affected the R33-mediated reduction of the TAU ratio, we treated wild-type purified neurons with the gamma-secretase inhibitor compound E, which inhibits the generation of Aβ but increases the amount of the β-CTF of APP. Interestingly, R33 treatment further reduced the amount of Aβ remaining after compound E treatment ([Figure 5](#fig5){ref-type="fig"}E). The presence of compound E had no effect on the decrease pTAU/tTAU ratio after treatment with R33 ([Figure 5](#fig5){ref-type="fig"}F). Taken together, these data suggest that while the pTAU/tTAU reduction by R33 is highly correlative with Aβ peptide levels, modulation of APP processing, either up or down, does not change the R33-mediated reduction of pTAU.

R33 Reduction of Phospho-TAU in hiPSC-Derived Neurons Is Independent of APP Expression {#sec2.5}
--------------------------------------------------------------------------------------

Because hiPSCs are amenable to genome engineering, we generated an *APP* knockout (APP KO) hiPSC line from our parental APP duplication hiPSC line (APP^Dp^1) using CRISPR/Cas9 genome editing. APP KO hiPSCs were generated from FAD APP^Dp^ parental line by excision of one copy of *APP* and the introduction of two premature stop codons via non-homologous end-joining in the remaining copies (R. Van der Kant et al., personal communication; [Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). APP KO hiPSCs have no detectable APP protein by western blot analysis ([Figure S5](#mmc1){ref-type="supplementary-material"}C). We differentiated and purified neurons from APP KO hiPSCs and confirmed that these neurons do not have detectable levels of secreted Aβ peptides by ELISA ([Figure 6](#fig6){ref-type="fig"}A). We next treated APP KO neurons with R33 and observed decreased pTAU from APP KO neurons ([Figure 6](#fig6){ref-type="fig"}B) with no change in tTAU ([Figure 6](#fig6){ref-type="fig"}C), again leading to a significant reduction in the pTAU/tTAU ratio in APP KO neurons ([Figure 6](#fig6){ref-type="fig"}D). When APP KO neurons were transduced with sh*VPS35*-c, we documented a significant increase in the amount of pTAU ([Figure 6](#fig6){ref-type="fig"}E), and this effect was confirmed with a second shRNA, sh*VPS35*-d ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Finally, we tested whether VPS35 knockdown would change the effect of R33 on pTAU levels in APP KO neurons. Interestingly, knockdown of VPS35 did not affect the R33-mediated reduction in pTAU in these cells ([Figure S6](#mmc1){ref-type="supplementary-material"}B). However, this result is not overly surprising, as we have an incomplete loss of VPS35 (∼50%) and the R33 chaperone is still stabilizing the remaining retromer. Indeed, previous work demonstrates that retromer stabilization chaperones continued to stabilize two of the three cargo-recognition core proteins (VPS29 and VPS35) under single knockdown conditions (sh*VPS26*) ([@bib25]). Taken together, these experiments suggest that retromer stability influences TAU phosphorylation and that this is mediated through an APP-independent mechanism. Furthermore, these data imply that retromer enhancement may be beneficial even under less than optimal retromer conditions, such as loss of VPS35 expression, a condition documented in AD patient tissue ([@bib40]).Figure 6Retromer Stabilization Decreases the pTAU/tTAU Ratio and Knockdown of Retromer Assembly Subunit VPS35 Increases pTAU/tTAU Ratio Independently of APP Expression in Human Neurons(A) APP KO neurons were generated from APP^Dp^ cells by CRISPR/Cas9 genome editing have no detectable levels of Aβ peptides.(B) APP KO neurons show a significant reduction in pTAU (Thr 231) after treatment with R33.(C) tTAU levels are not affected in APP KO neurons after treatment with R33.(D) The pTAU/tTAU ratio is significantly reduced in APP KO neurons after treatment with R33.(E) APP KO neurons transduced with VPS35 shRNA show a significant increase in pTAU/tTAU ratio compared with scrambled shRNA (SCR shRNA).n = 3 independent experiments per treatment/condition. For each comparison, a two-tailed t test was performed. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. NS, nonsignificant. Error bars represent SD. See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

In this work, we demonstrate that a small molecule stabilizer of the retromer complex reduces endogenous cellular AD phenotypes in human neurons. This small molecule, R33, has been previously shown to reduce Aβ peptides and decrease APP in early endosomes, consistent with its *in vitro* action as a pharmacological chaperone that stabilizes the retromer complex ([@bib25]) ([@bib12]). We extended this work in human neurons to test how retromer stabilization affects TAU phosphorylation, another critical pathologic phenotype in AD and one that correlates more highly with cognitive decline than the presence of amyloid plaques in patients ([@bib1]). In this work, we demonstrate that retromer stabilization in human neurons reduces TAU phosphorylation at two epitopes, suggesting that this strategy may be beneficial for pathologies extending beyond amyloid. Indeed, while the focus on Aβ as the premier pathological event has undoubtedly yielded insights into the disease, particularly for FAD, it is equally conceivable to envision a "dual-pathway" hypothesis where an upstream molecular driver influences Aβ and TAU pathologies separately ([@bib39]). This may especially be the case for SAD, where immense genetic heterogeneity and complex environmental interactions have unknown influences on the course of the disease. Here we decouple the effect of retromer stabilization on both APP processing and TAU phosphorylation using gene-edited hiPSC-derived neurons. In both neurons engineered to have 2- to 3-fold higher amounts of Aβ (APP^Swe^) or neurons engineered to not express APP and which have no detectable Aβ (APP KO), retromer stabilization decreases TAU phosphorylation to the same extent, suggesting that manipulation of endocytic trafficking via retromer may be an upstream driver of these two pathologies independently from one another. This approach of gene editing in pluripotent stem cells allows the dissection of relevant disease biology in a human-specific system.

The link between retromer regulation of endosomal trafficking and TAU phosphorylation is currently unclear, although compelling studies are emerging to suggest that endocytic trafficking may directly affect TAU pathology. [@bib27], suggest that monomeric TAU is endocytosed from the extracellular space and its transit through endosomes facilitates TAU seeding and aggregation. Work in flies demonstrates that removing cathepsin D, a retromer cargo and integral enzyme in lysosomal degradation, exacerbates TAU-induced neurodegeneration ([@bib20]). Extracellular TAU can be taken up and propagated via exosomes in microglia, the resident immune cells of the CNS ([@bib2]), and retromer deficiency impairs the recycling of TREM2 protein, a product of the *TREM2* gene that is also associated with increased AD risk, which can inhibit microglial activation ([@bib46]). Developing methods of improving endocytic trafficking and function in multiple CNS types will likely be protective in many neurodegenerative disorders, underscoring the importance of elucidating the role of the endocytic network in both Aβ and TAU pathology. Finally, we highlight the potential of hiPSC models to confirm and elaborate on work done in non-human systems. We have replicated work previously published in mice to show that retromer stabilization decreases pathogenic APP processing ([@bib25]) and extended our studies to show a beneficial effect of retromer stabilization on TAU in human neurons, which, to our knowledge, has not been documented previously. Furthermore, we demonstrate that this process correlates with, but is not dependent upon, APP processing.

Considering that the current failure rate of AD clinical trials is very high ([@bib31]), new therapeutic strategies aimed at improving retromer and other endocytic network component function are likely to be promising therapeutic options. Indeed, recent genetic findings implicate endosomal and vesicular trafficking genes in both early- and late-onset AD ([@bib4], [@bib22], [@bib36]). For that reason, and because defects in the endocytic pathway occur early in AD pathogenesis, targeting this pathway represents a valid cell biological target for therapeutic development ([@bib41]).

The use of hiPSCs, which can be differentiated into all cell types of the CNS, represents an ideal model to test novel and existing drugs and other therapies in a preclinical system. In particular, the advantage of a system that does not rely on overexpression of disease proteins has already been shown: patient-derived neurons behave differently from APP-overexpressing cell lines and animal AD model-derived neurons when exposed to drug candidates, such as gamma-secretase modulators ([@bib24]). Recently, cortical neurons from hiPSCs have been used to screen modulators of Aβ peptide length ([@bib7]), and work in scalable three-dimensional culture formats has shown detection of TAU aggregates in a quantifiable manner in 384-well plates ([@bib26]), representing a growing technology involving complex cellular interactions that will likely be highly translational.

Abnormalities in the endo/lysosomal network are a common theme in multiple neurodegenerative disorders ([@bib17], [@bib38]), and retromer-related mutations or defects are implicated not only in AD, but Parkinson disease and Down syndrome, as well as other non-neurological conditions ([@bib5]). Our work, for the first time, examines a small molecule that enhances the function of retromer, which is an integral component of the endosomal network, using human neurons. This pharmacologic chaperone, R33, demonstrated pronounced and potentially beneficial effects on the two main pathological molecules in AD: Aβ and pTAU. We predict that using hiPSCs, both from patients and isogenic lines with key mutations or variants, to test and screen novel therapeutic molecules and other therapeutic strategies will represent a major advance in therapeutic development for AD and other complex neurodegenerative disorders.

Experimental Procedures {#sec4}
=======================

Cell Lines and Cell Culture {#sec4.1}
---------------------------

All patient-derived hiPSC lines were generated by four-factor reprogramming and have been previously characterized and published ([@bib18], [@bib47]). Briefly, hiPSCs were maintained on a mouse embryonic fibroblast (MEF) feeder layer in HUES medium and were routinely tested for mycoplasma. NSCs and neurons were generated using previously described methods ([@bib18], [@bib48]) and purified by fluorescence-activated cell sorting (FACS). After FACS purification, depending on the percentage of neurons in each differentiation, 2 to 4 independent purified cultures were re-plated for each experiment. From these independent cultures and for each assay, 2 to 4 technical replicates from each well were analyzed.

CRISPR/Cas9 Gene Editing {#sec4.2}
------------------------

Genome-edited lines were generated using published protocols. Briefly, guide RNAs (gRNAs) to APP were generated using the Zhang Lab Crispr design Web site at MIT ([crispr.mit.edu](http://crispr.mit.edu){#intref0010}) and cloned into vector px458 (Addgene) that co-expresses the Cas9 nuclease and GFP. hiPSCs were electroporated with the px458 plasmid containing the gRNAs to target APP. We generated the APP KO cells from our parental APP^Dp^ cell line (APP^Dp^1), first described in [@bib18]. To generate APP KO cells, no repair template was added. For generating the APP Swedish mutation, we targeted wild-type hiPSCs derived from J. Craig Venter ([@bib15]) and 120-bp single-stranded oligonucleotide was designed to have the 2-bp Swedish mutation (GA to TC, corresponding to exon 16 of APP). Electroporated hiPSCs were sorted for GFP and plated a clonal density on 10-cm MEF plates. After 1.5 to 2.0 weeks, sub-cloned colonies were picked and transferred to a 96-well plate. Colonies were spit in duplicate and one set was maintained for cell line generation and the other was analyzed for the mutation of interest by Sanger Sequencing. All gene-edited lines were digitally karyotyped as euploid by the Illumina Infinium HumanCoreExomeBeadChip, as has been previously described ([@bib47])

Drug Treatment and ELISA Assays {#sec4.3}
-------------------------------

Pure R55 and R33 were obtained from MedKoo Biosciences (products TPT-260 and TPT-172) and re-suspended at designated concentrations in a solution of 50% DMSO/50% double-distilled H~2~O at low pH (pH 4.3). For these studies, R33 was used for every experiment. Purified neurons were treated with R33 or vehicle (DMSO/H~2~O) for 72 hr and then harvested for analysis. For Aβ and TAU ELISA assays, purified neurons were seeded at 200,000 cells/well of a 96-well plate. After treatment, cell culture media and cell lysate were harvested from triplicate wells and run on Aβ Triplex ELISA plates and pTAUThr231/tTAU ELISA plates (Meso Scale Discovery). Protein concentrations were determined by BCA assay (Pierce) and Aβ levels were normalized to the amount of total protein.

Western Blotting {#sec4.4}
----------------

Cell lysates were run on NuPAGE 4% to 12% Bis-Tris Gels, transferred to nitrocellulose membranes, and probed with antibodies to VPS35 (Abcam \#ab57632), APP (Life Tech \#512700), TAU (Thermo \#MN1000 and MN\#1020). Quantification of western blots was performed on the Odyssey system and using ImageJ software.

shRNA Design and Virus {#sec4.5}
----------------------

shRNAs against VPS35 were ordered from Origene (\#TL300553). VPS35 and scrambled control shRNAs were packed into lentivirus using HEK293FT cells. Virus was purified by PEG-it and cells were transduced with lentivirus for 72 hr. Knockdown of VPS35 was confirmed by qRT-PCR and western blot analysis.

gRNA, ssODN, and Primer Sequences {#sec4.6}
---------------------------------

gRNA to generate APP Swedish and APP KO cells: GGAGATCTCTGAAGTGAAGA TGG.

ssODN for APP Swedish homologous recombination 2-bp change in bold: TGATGTAATACAGGTTCTGGGTTGACAAATATCAAGACGGAGGAGATCTCTGAAGTGAA**TC**TGGATGCAGAATTCCGACATGACTCAGGATATGAAGTTCATCATCAAAAATTGGTACGT.

VPS35 primer for qRT-PCR: F primer, TGCCCACCAGACTATCAGTG; R primer, AGCTGCACTTGTAGAGAGGG.

Statistical Methods {#sec4.7}
-------------------

Statistics for all datasets were performed using GraphPad Prism. Normality for each dataset was assessed using the D\'Agostino-Pearson test. When data were normally distributed, a parametric two-tailed t test was used. The comparisons between multiple cells lines from different individuals usually resulted in non-normally distributed data and these data were analyzed using the Wilcoxon-signed rank test.
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